{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Cara Therapeutics, Inc."},"Symbol":{"label":"Symbol","value":"CARA"},"Address":{"label":"Address","value":"107 ELM STREET,9TH FLOOR, 4 STAMFORD PLAZA, STAMFORD, Connecticut, 06902, United States"},"Phone":{"label":"Phone","value":"+1 203 406-3700"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Cara Therapeutics Inc is an emerging biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features."},"CompanyUrl":{"label":"Company Url","value":"https://www.caratherapeutics.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Christopher A. Posner","title":"President, Chief Executive Officer & Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}